2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine
(Synonyms: 咪唑并二甲基吡啶) 目录号 : GC14445
An angiotensin II receptor antagonist
![2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine Chemical Structure](/media/struct/GC1/GC14445.png "2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine Chemical Structure")
Cas No.:133240-06-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine is a nonpeptidic angiotensin II receptor antagonist.
Angiotensin II is the critical pressor substance of the renin-angiotensin system (RAS). The angiotensin II system, a proteolytic cascade regulating hemodynamics and water and electrolyte balance, is able to contribute to hypertensive states in human. The effects of the octapeptide angiotensin I1 includs cardiac stimulation, vasoconstriction, stimulation of aldosterone synthesis and release, as well as renal reabsorption of sodium.
In vitro: In a previous study, 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine was synthezed by reduction of 2-amino-3-nitropyridine derivatives to the corresponding diaminopyridine which was then condensed with an appropriate carboxylic acid in polyphosphoric acid. In vitro activity study showed that 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine was a nonpeptidic angiotensin II receptor antagonist whose imidazo[4,5-b]pyridine scaffold had been used to examine plenty of positional substitutions in the development of orally active, long duration antihypertensive agents [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Mantlo, N. B.,Chakravarty, P.K.,Ondeyka, D.L., et al. Potent, orally active Imadazo[4,5-b]pyridine-based angiotensin II receptor antagonists. Journal of Medicinal Chemistry 34(9), 2919-2922 (1991).
| Cas No. | 133240-06-9 | SDF | |
| 别名 | 咪唑并二甲基吡啶 | ||
| 化学名 | 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine | ||
| Canonical SMILES | CC1=CC(C)=C2C(N1)=NC(CC)=N2 | ||
| 分子式 | C10H13N3 | 分子量 | 175.2 |
| 溶解度 | ≥ 5.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7078 mL | 28.5388 mL | 57.0776 mL |
| 5 mM | 1.1416 mL | 5.7078 mL | 11.4155 mL |
| 10 mM | 0.5708 mL | 2.8539 mL | 5.7078 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。